FL116
Not specified
Not specifiedPipeline
Key Facts
About Forlong Biotechnology
Clinical-stage biotech developing novel cytokine therapeutics for oncology using proprietary synthetic cytokine platforms.
View full company profileTherapeutic Areas
Other Not specified Drugs
| Drug | Company | Phase |
|---|---|---|
| FL117 | Forlong Biotechnology | Not specified |
| FL118 | Forlong Biotechnology | Not specified |
| FL301 | Forlong Biotechnology | Not specified |
| JSKN016 | AlphaMab Oncology | Phase 1 |
| JSKN033 | AlphaMab Oncology | Phase 1 |
| JSKN022 | AlphaMab Oncology | Phase 1 |
| JSKN027 | AlphaMab Oncology | Phase 1 |
| KN019 | AlphaMab Oncology | Phase 1 |
| New TCM Formulations | China SXT Pharmaceuticals | Research / Pre-clinical |
| Long-acting Leronlimab | CytoDyn | Preclinical |
| SR2162 | SIMR (Australia) Biotech | IND Approved |
| Collaborative Program with Ferring | PharmaBiome | Research |